FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1976158428> ?p ?o ?g. }

• W1976158428 endingPage "1089" @default.
• W1976158428 startingPage "1084" @default.
• W1976158428 abstract "To evaluate mifepristone (RU-486) in patients with castration-resistant prostate cancer (CRPC), with a correlative assessment of serum androgens and androgen metabolitesThe androgen receptor (AR) is critical in the development and progression of prostate cancer, but available antiandrogens incompletely abrogate AR signalling. Mifepristone is a potent AR antagonist that functions by competing with androgen, preventing AR coactivator binding and by enhancing binding of AR corepressors. Patients with CRPC were treated with mifepristone 200 mg/day oral until disease progression. Testosterone, dihydrotestosterone (DHT), androstenedione, dihydroepiandrosterone sulphate and the testosterone metabolite 3 alpha-diol G, were measured at baseline and during therapy.Nineteen patients were enrolled between April and August 2005; they were treated for a median (range) of 85 (31-338) days. The median prostate-specific antigen (PSA) level at enrollment was 22.0 (3.0-937.2) ng/mL. No patient had a PSA response (>50% reduction in PSA). Six patients had stable disease for a median of 5.5 months. After 1 month, adrenal androgens were increased and testosterone and DHT increased by 91% and 80%, respectively, compared to baseline.Mifepristone had limited activity in patients with CRPC, and stimulated a marked increase in adrenal androgens, testosterone and DHT. We hypothesise that inhibition of glucocorticoid receptor by mifepristone resulted in an increase in adrenocorticotropic hormone and subsequent increase in adrenal androgens, and that their conversion by tumour cells to testosterone and DHT probably limited the efficacy of mifepristone. These data emphasize the continued importance of alternative androgen sources in AR signalling in CRPC." @default.
• W1976158428 created "2016-06-24" @default.
• W1976158428 creator A5005766189 @default.
• W1976158428 creator A5017925159 @default.
• W1976158428 creator A5018292930 @default.
• W1976158428 creator A5023517416 @default.
• W1976158428 creator A5043769628 @default.
• W1976158428 creator A5045746656 @default.
• W1976158428 creator A5051729520 @default.
• W1976158428 creator A5054383262 @default.
• W1976158428 creator A5055950098 @default.
• W1976158428 creator A5087350413 @default.
• W1976158428 date "2008-05-01" @default.
• W1976158428 modified "2023-10-14" @default.
• W1976158428 title "A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones" @default.
• W1976158428 cites W1993284512 @default.
• W1976158428 cites W2002218819 @default.
• W1976158428 cites W2002372801 @default.
• W1976158428 cites W2014476883 @default.
• W1976158428 cites W2022635468 @default.
• W1976158428 cites W2031454470 @default.
• W1976158428 cites W2032777224 @default.
• W1976158428 cites W2055013229 @default.
• W1976158428 cites W2062865195 @default.
• W1976158428 cites W2067890225 @default.
• W1976158428 cites W2074369446 @default.
• W1976158428 cites W2077301757 @default.
• W1976158428 cites W2078400569 @default.
• W1976158428 cites W2079039801 @default.
• W1976158428 cites W2081365151 @default.
• W1976158428 cites W2114185421 @default.
• W1976158428 cites W2116419432 @default.
• W1976158428 cites W2136294116 @default.
• W1976158428 cites W2136657922 @default.
• W1976158428 cites W2140855177 @default.
• W1976158428 cites W2146104410 @default.
• W1976158428 cites W2167223040 @default.
• W1976158428 cites W2329037156 @default.
• W1976158428 cites W2340799873 @default.
• W1976158428 cites W2411839432 @default.
• W1976158428 cites W4247824485 @default.
• W1976158428 doi "https://doi.org/10.1111/j.1464-410x.2008.07509.x" @default.
• W1976158428 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18399827" @default.
• W1976158428 hasPublicationYear "2008" @default.
• W1976158428 type Work @default.
• W1976158428 sameAs 1976158428 @default.
• W1976158428 citedByCount "61" @default.
• W1976158428 countsByYear W19761584282012 @default.
• W1976158428 countsByYear W19761584282013 @default.
• W1976158428 countsByYear W19761584282014 @default.
• W1976158428 countsByYear W19761584282015 @default.
• W1976158428 countsByYear W19761584282016 @default.
• W1976158428 countsByYear W19761584282017 @default.
• W1976158428 countsByYear W19761584282018 @default.
• W1976158428 countsByYear W19761584282019 @default.
• W1976158428 countsByYear W19761584282020 @default.
• W1976158428 countsByYear W19761584282021 @default.
• W1976158428 countsByYear W19761584282022 @default.
• W1976158428 countsByYear W19761584282023 @default.
• W1976158428 crossrefType "journal-article" @default.
• W1976158428 hasAuthorship W1976158428A5005766189 @default.
• W1976158428 hasAuthorship W1976158428A5017925159 @default.
• W1976158428 hasAuthorship W1976158428A5018292930 @default.
• W1976158428 hasAuthorship W1976158428A5023517416 @default.
• W1976158428 hasAuthorship W1976158428A5043769628 @default.
• W1976158428 hasAuthorship W1976158428A5045746656 @default.
• W1976158428 hasAuthorship W1976158428A5051729520 @default.
• W1976158428 hasAuthorship W1976158428A5054383262 @default.
• W1976158428 hasAuthorship W1976158428A5055950098 @default.
• W1976158428 hasAuthorship W1976158428A5087350413 @default.
• W1976158428 hasConcept C121608353 @default.
• W1976158428 hasConcept C126322002 @default.
• W1976158428 hasConcept C134018914 @default.
• W1976158428 hasConcept C2777911890 @default.
• W1976158428 hasConcept C2778826759 @default.
• W1976158428 hasConcept C2779234561 @default.
• W1976158428 hasConcept C2779279991 @default.
• W1976158428 hasConcept C2779881493 @default.
• W1976158428 hasConcept C2780192828 @default.
• W1976158428 hasConcept C54355233 @default.
• W1976158428 hasConcept C61367390 @default.
• W1976158428 hasConcept C71315377 @default.
• W1976158428 hasConcept C71924100 @default.
• W1976158428 hasConcept C86803240 @default.
• W1976158428 hasConceptScore W1976158428C121608353 @default.
• W1976158428 hasConceptScore W1976158428C126322002 @default.
• W1976158428 hasConceptScore W1976158428C134018914 @default.
• W1976158428 hasConceptScore W1976158428C2777911890 @default.
• W1976158428 hasConceptScore W1976158428C2778826759 @default.
• W1976158428 hasConceptScore W1976158428C2779234561 @default.
• W1976158428 hasConceptScore W1976158428C2779279991 @default.
• W1976158428 hasConceptScore W1976158428C2779881493 @default.
• W1976158428 hasConceptScore W1976158428C2780192828 @default.
• W1976158428 hasConceptScore W1976158428C54355233 @default.
• W1976158428 hasConceptScore W1976158428C61367390 @default.
• W1976158428 hasConceptScore W1976158428C71315377 @default.
• W1976158428 hasConceptScore W1976158428C71924100 @default.
• W1976158428 hasConceptScore W1976158428C86803240 @default.

• next